Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

With the data on the study’s other goals in hand, Pfizer said it plans to discuss with the FDA the potential for full approval of Braftovi in metastatic colorectal cancer. The company also plans ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

SoundHound AI develops voice AI systems for automotive, retail, and healthcare organizations. Palantir's market cap is now ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter ... is generally consistent with the profile of abemaciclib and what has ...

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

The company’s first product, a palatable anti-parasitic drug, made to taste like toffee, united Pfizer’s skills as ... and a series of high-profile failures of drugs in development, such ...